<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980382</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-04-107</org_study_id>
    <nct_id>NCT00980382</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma</brief_title>
  <official_title>A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, single center, nonrandomized study, consisting of a
      dose-escalating phase I study in advanced solid cancer and a subsequent phase II study in
      metastatic gastric cancer. In phase I study, we aim to determine the MTD and the recommended
      dose of S-1 combined with docetaxel given every 3 weeks. Dose level and escalating schedule
      are followings

        -  S-1(level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14)

        -  Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) mixed in d5w 200 ml iv over 60 min:
           Days 1, 8with dexamethasone 8 mg po q 12hr for 3 days (total 6 doses: D0-2)and
           parenteral pheniramine maleate 1 ample (45.5mg) before docetaxel
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>*phase I study:the maximum tolerated doses (MTD)of S-1 and docetaxel,recommended dose for subsequent phase II study *phase II study: evaluation of efficacy and toxicities of this new combination regimen in metastatic</measure>
    <time_frame>During chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the time to progression and overall survival</measure>
    <time_frame>During study period</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">85</enrollment>
  <condition>Stomach Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1, Docetaxel</intervention_name>
    <description>Phase I study
S-1 (level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14
Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) iv : Days 1, 8
Phase II study
S-1 (80mg/m2/day) q 12 hours po Days 1-14
Docetaxel (35 mg/m2) iv : Days 1, 8</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In phase I:histologically or cytologically confirmed advanced solid Cancer In phase
             II:histologically or cytologically confirmed metastatic gastric adenocarcinoma

          2. Age: over 18 years

          3. No prior chemotherapy or radiotherapy (including any adjuvant hemotherapy) in phase II
             portion Previous chemotherapy up to two regimens (including adjuvant chemotherapy) is
             allowed in phase I portion; patients are required to have discontinued chemotherapy,
             immunotherapy, and radiotherapy for at least 4 weeks before entry into phase I portion

          4. Disease status must be that of measurable disease defined as: Lesions that can be
             accurately measured in at least one dimension &gt;10 mm with spiral CTscan and palpable
             LN (including supraclavicular LN) in physical examination.

          5. Performance status: ECOG 0-2

          6. Adequate major organ function including the following Hematopoietic function:
             WBC&gt;4,000/mm3 or ANC&gt; 2,000/mm3, Platelet count Â³ 100,000/mm3Hepatic function:
             Bilirubin UNL (Upper normal limit), AST/ALT levels 2.5X UNL Renal function: Creatinine
             UNL

          7. Patients should sign an informed consent

        Exclusion Criteria:

          1. Inadequate cardiovascular function: New York Heart Association class III or IV heart
             disease Active angina or myocardial infarction within the past 6 monthsHistory of
             significant ventricular arrhythmia requiring medication with antiarrhythmics or
             significantconduction system abnormality

          2. Other malignancy within the past 3 years except nonmelanomatous skin cancer or
             carcinoma in situ of the cervix

          3. Pregnant or nursing women

          4. Serious concurrent infection or nonmalignant illness that is uncontrolled or whose
             control may be jeopardized by complications of study therapy

          5. Psychiatric disorder that would preclude compliance

          6. Patients receiving a concomitant treatment with drugs interacting with S-1 or
             docetaxel: flucytosine, phenitoin, warfarin et al.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sook Ryun Park, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center Korea</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <last_update_submitted>September 18, 2009</last_update_submitted>
  <last_update_submitted_qc>September 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Sook Ryun Park/MD</name_title>
    <organization>National Cancer Center, Korea</organization>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>phase I/II</keyword>
  <keyword>Combination chemotherapy</keyword>
  <keyword>S-1</keyword>
  <keyword>Docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

